Signal detection requires ratings reliability throughout a clinical trial. The confirmation of sitebased rater scores by a second, independent and blinded rater is a reasonable metric of ratings reliability. We used audio-digital pens to record site-based interviews of the Montgomery-Asberg Depression Rating Scale (MADRS) in a double-blind, placebo controlled trial of a novel antidepressant in treatment resistant depressed patients. Blinded, site-independent raters generated "dual" scores that revealed high correlations between site-based and siteindependent raters (r= 0.940 for all ratings) and high sensitivity, specificity, predictive values, and kappa coefficients for treatment response and non-response outcomes using the site-based rater scores as the standard. The blinded raters achieved an 89.4% overall accuracy and 0.786 kappa for matching the treatment response or non-response outcomes of the site-based raters. A limitation of this method is that independent ratings depend on the quality of site-based interviews and patient responses to the site-based interviewers. Nonetheless, this quality assurance strategy may have broad applicability for studies that use subjective measures and wherever ratings reliability is a concern. "Dual" scoring of recorded site-based ratings can be a relatively unobtrusive surveillance strategy to confirm scores and to identify and remediate rater "outliers" during a study.
Introduction
More than 50% of recently conducted randomized, placebocontrolled trials of antidepressant medications have failed to differentiate the candidate drug from placebo (Hooper and Amsterdam, 1999; Khan et al., 2002 Khan et al., , 2003 Papakostas and Fava, 2009; Khin et al., 2011) . Beyond the actual efficacy of the candidate drug, clinical trials can fail because of poor study design as well as study execution (Fava et al., 2003) . Some of the inherent aspects of the design of randomized clinical trials may influence response expectations and may reinforce placebo effects. For instance, both the requisite consenting process and the ritualized, repetitive, and often supportive study procedures conducted at each visit can foster expectations and conditioned learning (Miller et al., 2009) . The true drug effect may be only a fraction of the total symptomatic change that occurs during the course of a study (Lambert, 1992; Kirsch and Sapirstein, 1998; Miller et al., 2009) . Some placebo response is inevitable in a well-conducted doubleblind trial. The management of these inherent challenges requires ratings reliability (scoring accuracy and ratings consistency) throughout the trial to improve the predictive value of the test. In fact, it is well established that ratings reliability is a key factor to achieve study success (Muller and Szegedi, 2002; Kobak et al., 2005 Kobak et al., , 2007 Targum, 2006) . Kobak et al. (2007) identified poor inter-rater reliability, poor interview quality, and rater scoring biases as major factors causing clinical trials to fail. It has also been shown that poor ratings reliability adversely affects the power to detect a significant signal (Leon and Marzak, 1995; Perkins et al., 2000; Muller and Szegedi, 2002) . One method to evaluate ratings reliability is to examine ratings precision (reproducibility of the same assessment) by using two independent raters to assess the same patient. We have adopted this two-rater strategy and explored the utility of "dual" (paired) scoring by using blinded, site-independent raters to score audio-digital recordings of site-based interviews in studies of Major Depressive Disorder (MDD) and schizophrenia (Asgharnejad et al., 2012; Targum et al., 2012; Leigh-Pemberton et al., 2014) .
In this study, we examined the sensitivity, specificity, predictive values, and kappa coefficients of blinded, siteindependent "dual" scores to match the treatment outcome results of site-based scores of the same patient in a doubleblind, placebo-controlled trial of treatment resistant depressed patients.
Experimental procedures
Data for this analysis of "dual" (paired) ratings came from a quality assurance program that was employed in a study of CX157 (TriRima s ) versus placebo for patients with treatment resistant depression (Clinicaltrials.gov identifier: NCT00739908). CX157 is a reversible and selective monoamine oxidase-A inhibitor (Anderson et al., 1993) . Eligible subjects met DSM-IV-TR criteria for Major Depressive Disorder (MDD) and had sufficient documentation of inadequate treatment responses to at least one but no more than three adequate courses of antidepressant medication in their current episode as measured by the MGH-antidepressant treatment response questionnaire (APA, 1994; Chandler et al., 2010) . The primary efficacy measure was the change in the total MADRS score from baseline to endpoint in the modified intent to treat (mITT) population. The mITT population included those subjects in the safety analysis set who took at least one dose of study medication and had MADRS total scores at randomization and at least one post-treatment visit.
The study was conducted in compliance with Institutional Review Board (IRB), informed consent regulations, and International Conference on Harmonization (ICH) for Good Clinical Practice (GCP) Guidelines at 29 clinical trial sites in the United States. All potential subjects signed informed consent to participate in the study. Eligible patients were given either CX157 at 125 mg B.I.D. or matching placebo tablets in a 1:1 double-blind, randomization design for 6 weeks.
Study eligibility included a minimum total score on the 17-item Hamilton depression rating scale at the screen visit (Hamilton, 1960) . However, the primary efficacy measure for the study was the Montgomery-Asberg Depression Rating Scale (MADRS) that was administered using a Structured Interview Guide (SIGMA) at the baseline visit and the post-randomization visits at weeks 1, 2, 4, and 6 (Montgomery and Asberg, 1979; Williams and Kobak, 2008) . The guide was developed to enhance inter-rater reliability by standardizing the prompts asked by each rater for each of the ten MADRS items.
All site-based and site-independent raters participated in a comprehensive rater training and certification program that included didactic presentations, observation of expert MADRS video interviews, and demonstration of MADRS scoring competency via inter-rater reliability (IRR) assessments of two MADRS video interviews. Light's kappa's (a multi-rater version of Cohen's kappa) was used to calculate IRR (Warrens, 2010) . Site-based raters were also required to demonstrate interviewing competency skills via mock MADRS interviews. As part of this program, the site-based raters were trained to conduct the MADRS interviews using an audiodigital recording pen. The pens simultaneously audio-record the MADRS interview and digitally copy accompanying written notes that are captured on specially manufactured source books. The recorded interviews were electronically forwarded to Clintara LLC (Boston, MA) for random assignment to six site-independent raters who had also completed the MADRS training requirements. The siteindependent raters were blinded to the study visit and trial site and generated their "dual" scores by listening to the audio recording and reading the site-based rater's accompanying digital notes. The digital notes sent to the blinded rater did not include the site-based rater's scores.
All patients consented to audio-digital recording of site-based MADRS interviews as part of their consent to participate in the study. In this study, 100% of the interviews were recorded and collected throughout the study as part of the quality control program and 20-25% of the submitted recordings were randomly assigned for scoring by the site-independent raters. Initially, "dual" scoring was randomly assigned to all sites and all raters. As the study progressed, some rater "outliers" were identified in-study for additional "dual" ratings surveillance. All recordings were reviewed for completeness and sound quality prior to "dual" scoring. As part of the review plan, a higher percentage of baseline and week 6 (endpoint) MADRS interviews were independently scored in order to facilitate treatment outcome comparisons.
Site-based treatment outcome data for this study has been reported elsewhere . In this analysis, we examined the scoring variance, intra-class correlation, and absolute discordance between the available "dual" (paired) site-based and site-independent MADRS scores. Scoring discordance reflects the deviation (total score difference) of the site-independent scores from the paired site-based MADRS scores in either direction. The discordance rate was calculated as the number of "dual" scores that were greater than 1 standard deviation of the mean total MADRS score for the total mITT population at baseline (46 points in this study). The choice of a broad, rather than narrow concordance range was based upon the quality assurance (QA) focus of the "dual" ratings strategy to identify rater "outliers" for remediation. In addition, we recognized that some scoring variability was inevitable between live site-based interviews and independent raters who listen to the recordings but do not observe the patient during these interviews.
Throughout the study, site-based rater "outliers" whose "dual" scores were discordant were identified for remediation. A second, independent rater listened to the flagged "discordant" interviews to affirm the scoring discordance. Rater remediation included telephone discussions with the site-based rater to review individual scoring differences and interview style, and was followed by increased vigilance of their subsequent interviews. Raters whose scoring discordance did not improve could be removed from the study. As part of the overall QA program, ongoing "dual" data from all raters were accumulated and reviewed throughout the study to ascertain whether additional, mid-study rater training was necessary for the whole group.
In this study, treatment response was defined as a MADRS score improvement of Z50% between the baseline and endpoint measurement. We examined the sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) of the blinded, siteindependent raters to match the response/non-response treatment outcome status of the site-based rater MADRS scores used as the standard for comparison (Bland, 2000) . Finally, overall response accuracy for each group and the entire sample was calculated as all true CX157 positives (treatment responders) and true placebo negatives (placebo non-responders) divided by all "dual" scored subjects based on the site-based outcomes as the standard (Bland, 2000) . Additional statistical analyses included intra-class correlation (ICC), the kappa coefficient, and Student's t test as appropriate.
Results

Treatment results for the mITT population
597 subjects were screened and 360 were randomized to either CX157 treatment (n = 182) or placebo (n= 178). 353 patients qualified for the modified intent to treat population: mITT (CX157, n = 176; placebo, n= 177). At the baseline (randomization) visit, the mean total MADRS score for the mITT population was 32.576.1 (SD) for CX157 and 32.076.3 for the placebo group. At week 6, the mean total MADRS score in the mITT population was 23.3712.81 (SD) for CX157 and 22.2712.3 for the placebo group. Treatment response analyses for the mITT population revealed a 33.0% positive response for the CX157 group and a 31.1% placebo response. As previously reported, LOCF and MMRM analyses of the mITT population revealed no statistically significant differences in the changes of the total MADRS score between groups at any time point from randomization to week 6 .
MADRS interview length
There were 1664 MADRS interviews completed across 5 study visits (the baseline visit and four post-randomization visits). The mean interview length of the recorded MADRS interviews was 25:1378:36 (SD) minutes at baseline and 19:3177:49 for all post-randomization interviews. The mean post-randomization MADRS interview length was significantly less than the baseline interview (p= 0.0001). Interview lengths ranged from 9:50 to 63:20 min at baseline and 6:20 to 47:33 min post-randomization (median interview length was 23:30 min at baseline and 16:17 min post-randomization). MADRS interview length was not correlated with symptom severity as measured by the total MADRS score at baseline (r = À0.035) and was weakly correlated with severity at the post-randomization visits (r = 0.306).
3.3. "Dual" score treatment outcome comparisons 58 site-based and 7 site-independent raters participated in the rater training and certification program and were qualified to score the MADRS in this study. Light's kappa statistic for the two MADRS interviews used for IRR were κ= 0.619 and 0.809 respectively for all raters.
374 "dual" scores were available across the 5 study visits (22.5% of all MADRS interviews). This sample of "dual" sitebased MADRS scores was comparable to all of the total MADRS scores and change from baseline scores collected from the entire study population during the study. Mean total MADRS scores were 26.5710.8 for the 374 "dual" scored site-based MADRS scores across all visits and 26.3710.5 for all 1664 collected scores (p= ns). There were 154 "dual" scores available at baseline, 39 at the postrandomization week 1, 30 at week 2, 35 at week 4, and 116 "dual" scores available at week 6 (endpoint).
Mean total MADRS scores were comparable between sitebased and site-independent raters at all visits for the 354 paired "dual" scores. Mean total MADRS scores for the paired 154 "dual" baseline scores were 32.4575.98 (SD) for sitebased raters and 32.0276.15 for site-independent raters (p=0.530). The mean total MADRS scores at week 6 for the paired 116 "dual" scores were 19.52712.56 for the sitebased raters and 20.03711.92 (SD) for the site-independent raters (p=0.748). The intra-class correlation was r=0.865 at baseline (randomization) and improved to r=0.913, 0.945, 0.945, and 0.969 at the four subsequent post-randomization visits (r=0.951 for all post-randomization visits combined). Fig. 1 displays the scoring discordance between sitebased and site-independent raters for all 374 "dual" scored interviews. Site-based "dual" scores deviated from siteindependent scores between 9 points higher and 7 points lower at baseline and 10 points higher and 12 points lower post-randomization. 23 of the 374 "dual" scores (6.2%) were discordant using a total score deviation between site-based and site-independent ratings of 46 points in either direction as the discordance range. Four of the 58 site-based raters were identified as rater "outliers" and required rater remediation during the study; no raters were removed from the study.
Data for treatment outcome analyses were available from 85 pairs of "dual" MADRS interviews that were obtained at baseline and week 6 (or last observation carried forward) for the same patient. We calculated the outcome response matches (response/non-response) achieved by the blinded, site-independent raters for both the CX157 treatment group and placebo group using the site-based treatment response outcomes as the standard (Table 1) . The CX157 group sensitivity was 12/16 (75.0%%), specificity was 17/18 (94.4%), PPV was 12/13 (92.3%), and NPV was 17/21 (81.0%%). The placebo group sensitivity was 21/24 (87.5%), specificity was 26/27 (96.3%), PPV was 21/22 (95.5%), and NPV was 26/29 (89.7%). Treatment response accuracy was 85.3% for the CX157 group, 92.2% for the placebo group, and 89.4% for the entire population. Cohen's kappa coefficient was 0.702 for the CX157 group, 0.853 for the placebo group, and 0.786 for the entire population.
Discussion
In this study, "dual" ratings were used to compare sitebased MADRS interviews with blinded, site-independent ratings based upon audio-digital recordings of the sitebased interviews. The primary purpose of the "dual" ratings comparison was to identify rater "outliers" for remediation or removal from the study.
As part of this program, we used these "dual" data to evaluate the ability of the site-independent raters to confirm the site-based MADRS scores and the treatment outcome status. The site-independent raters were blinded to all other study information and did not know the study site, the study visit being assessed, or the site-based rater's score. The "dual" scores revealed high correlations between the site-based and site-independent raters at all visits, a low discordance rate (6.2%), and high sensitivity, specificity, and predictive values for the response/ non-response outcome status. The intra-class correlations between site-based and independent raters increased at each visit after baseline (r =0.865) and was ultimately r = 0.969 at the last visit.
Most of the 58 site-based raters were experienced with the MADRS interview and had participated in surveillance programs in the past. Hence, the high correlation observed in this study was due in part to their participation in previous programs prior to this study. Four of the sitebased raters were identified as "outliers" based upon a higher rate of discordant "dual" scores identified early in the study. These raters were remediated and their "dual" Fig. 1 Total MADRS "dual" score deviations between site-based and site-independent raters (n= 374). *Positive deviations (to the right) reflect site-based scores that were higher than site-independent scores; alternatively, negative score deviations reflect sitebased scores that were lower than the "dual" site-independent scores. Table 1 Comparison of treatment outcome responses of "dual" MADRS scores (n =85 pairs).
Site-based raters
Site-independent raters scoring performance subsequently improved and was consistent with all other raters as the study proceeded. In fact, the overall discordance rate improved during the study from 11.8% after 126 "dual" reviews, to 9.0% after 276 reviews, and finally 6.2% at the end of the study (n =374). We believe that the improving ICC and discordance rate noted during the course of the study reflects the beneficial effect of remediation, awareness of the ongoing surveillance program, and interviewing practice. It is likely that the mere fact of being observed has a positive impact on the quality of site-based interviews performed. The surveillance strategy of "watching" provides as a type of Hawthorne effect (McCarney et al., 2007) . Future studies might consider a nosurveillance comparison group to confirm the benefit of this strategy.
The overall response accuracy of the blinded, siteindependent raters to match the site-based treatment outcome status was 89.4% for the entire study population (Cohen's kappa coefficient = 0.786). The placebo group response accuracy using the MADRS was 92.2% in this study and nearly identical to the findings of Leigh-Pemberton et al. (2014) who reported 92.9% accuracy for the placebo group using the HamD-17 in another depression study. These findings confirm site-based ratings reliability (precision) and demonstrate that site-based raters can conduct competent and very scorable MADRS interviews. The structured interview guide (SIGMA) used in this study may have facilitated the close "match" between site-based raters and blinded independent raters, although unstructured formats have also worked in other studies (Targum, unpublished data) .
The mean interview length of the recorded MADRS interviews in this study was 25:1378:36 min at baseline and 19:3177:49 for all post-randomization interviews (p= 0.0001). The MADRS interview length was significantly shorter after randomization because some patients improved and endorsed fewer symptoms and may have required less time to conduct the interview. The recorded baseline (randomization) time is consistent with the findings of Williams and Kobak (2008) . In their reliability study conducted as part of the development of the structured interview guide for the MADRS (SIGMA), the mean interview length was 25.8710.04 min (range 5-56 min) over two separate visits. Williams and Kobak (2008) noted that the mean interview length of the second MADRS interview was over two minutes shorter than the first interview (t=2.38, p=0.02). Consequently, it is clear that the length of the recorded MADRS interviews were largely consistent with the expectations of the instrument authors.
Many of the site-based raters in this study had used the audio-digital pen recording technology in the past and were familiar with this assessment method. Overall, there were minimal technical difficulties with this surveillance strategy and the sites accepted and complied with the method utilized. In our experience across multiple studies, "dual" scoring of site-based ratings using the audio-digital pen methodology is a relatively unobtrusive surveillance strategy that can identify and remediate rater "outliers" during a study.
These findings suggest that "dual" site-independent scoring of recorded site-based interviews can be used to confirm ratings reliability and possibly enhance data integrity. However, there are several limitations that necessitate a cautious interpretation of the findings. These limitations include the study design, treatment outcome, and the "dual" ratings methodology itself. For instance, as noted above, the "dual" ratings strategy employed in this study did not include a comparison group without any surveillance such that some sites (or raters) had no recording requirement while others did. Hence, although it seems self-evident, it is not possible to assert that "dual" ratings surveillance definitely improved data integrity. Further, as the study did not achieve signal detection for the candidate drug, it is not possible to calculate a meaningful effect size comparison between site-based and site-independent raters.
The "dual" ratings methodology implemented for this specific study has some limitations that must be addressed. First, only 22.5% of the study population had "dual" scores for comparison. However, as noted in the results, there was no statistically significant difference between the total mean MADRS scores of the "dual" ratings subpopulation (n=374) compared to all 1664 MADRS interviews that were conducted during the study. Second, a demonstration of "dual" concordance between site-based and site-independent raters does not necessarily convey scoring accuracy. Although it is possible to determine whether "dual" scores are concordant, it is not possible to determine whether the concordant ratings are equally accurate or equally inaccurate. Of course, scoring accuracy, in contrast to reliability or consistency is an elusive target in CNS clinical trials. We have previously reported that each different rating method, including patient-reported outcomes have inherent limitations and that no single rating method is best (Targum, 2011; Targum et al., 2013) . Third, the audio-digital recording method chosen to obtain the "dual" scores in this study relies upon the interview quality of the site-based rater and the cooperation and information provided by the patient during that interview. There were no video observations of the patient in this study and no opportunity for the second, independent rater to ask more questions.
There are alternative ratings methods that have been used to obtain site-independent ratings that include video resources or entirely separate "live" telephone interviews by a second, remote rater. In our experience, video interviews can add an adverse measurement parameter for the observed patient (anxiety) and adds cost and burden to the site without substantially improving the "dual" ratings QA objective or ratings reliability (Targum et al., 2013) . Alternatively, an entirely separate interview conducted at a different time yields informational and temporal variance from the primary site-based rating and still requires good interviewing skills and a cooperative subject. In previous studies, we have reported that there was less correlation between secondary telephone or video interviews with sitebased interview ratings than with the "dual" ratings strategy (Targum, 2011) .
Clearly, ratings precision is only one challenge confronting randomized clinical trials. Ratings precision does not necessarily convey validity. In previous studies, we have reported that a patient's perception of his or her own symptoms may be significantly more severe than a clinician's assessment at the beginning of a clinical trial and significantly less severe at the end (Targum et al., 2013) . In addition, both site selection and subject validation prior to randomization are additional challenges that must be addressed as part of a quality assurance/external review program.
The capability to blindly confirm ratings and confirm treatment response/non-response outcomes without knowledge of the visit number or emerging adverse events suggest that this method may have utility as a "shadow" study when functional un-blinding is a concern. Despite the limitations noted above, the "dual" ratings quality assurance method may have broader applicability for studies that use subjective measures, have multiple raters at multiple trial sites, and wherever ratings precision is a concern.
Contributors
Dr. Targum participated in the design of the "dual" ratings component in the study design, undertook some of the statistical analysis, and wrote the drafts of the manuscript.
Dr. Asgharnesad participated in the study design and execution, statistical analysis, and writing of the study report that led to this manuscript.
Dr. Burch participated in the study design and execution, review of the data, and preparation of this manuscript.
Dr. Pendergrass participated in the study execution of the dual ratings, analysis of data, and contributed to the writing of this manuscript.
Chelsea Toner participated in the "dual" ratings analysis and study coordination and approved of the submission of the manuscript.
Role of funding source
Partial support for this study came from CeNeRx Pharmaceuticals during the clinical trial and from Krenitsky Pharmaceuticals Inc (KPI) who currently own the rights to TriRima s . However, the sponsor had no role in the analysis and/or interpretation of the data, the writing of this report, or the decision to submit the manuscript in its current form.
Author disclosures
Steven D. Targum has received consultation fees or vendor grants from the following: Acadia Pharmaceuticals, Abbott Labs, Acumen, Alcobra, Alkermes Inc., AstraZeneca, BioMarin, BrainCells Inc., CeNeRx, Civitas, Clintara LLC, Forum Pharmaceuticals, Euthymics, Forest Research, Functional Neuromodulation inc, Eli Lilly and Company, Intracellular Therapeutics Inc., Johnson & Johnson PRD, Medtronics, Methylation Sciences Inc., Mitsubishi Tanabe Pharma, NeoSync, Neurophage, Novartis Pharmaceuticals, Nupathe, Pfizer Inc., Prana Biotechnology Ltd., ReViva, Roche Labs, Sophiris, Sunovion, Targacept, Theravance, Transcept Pharmaceuticals, Inc.
J Cara Pendergrass is an employee of Clintara LLC. Chelsea Toner is an employee of Clintara LLC. Manny Asgharnejad was an employee of CeNeRx Pharmaceuticals at the time of this study and is now an employee of UCB Pharma.
Daniel J. Burch was an employee of CeNeRx Pharmaceuticals at the time of this study and is now an employee of PPD.
